Proning in ARDS: Mechanisms and Physiological Rationale Explained

Prone positioning (placing ARDS patients in prone position) is used for moderate-to-severe ARDS patients who may improve or benefit from this intervention. Benefits include improved oxygenation and reduced mortality in certain patient populations. However, positioning requires careful monitoring for complications such as endotracheal tube displacement, extubation, or hemodynamic instability. The technique was particularly used during the SARS-CoV-2 pandemic for severe patients.

This comprehensive section covers prone positioning for intubated patients with acute respiratory failure. The presenter details the required equipment including a gurney, bedding materials, pillows for thorax, pelvis, legs, and arms, collection bag for nasogastric tube, ventilator valves, emergency cart, aspirator, and nasogastric catheter. The preparation phase includes nasogastric tube placement, endotracheal tube verification, balloon inflation, oral hygiene, securing all tubes and catheters, peripheral IV placement, pleural drainage valve management, eye care, and skin hydration. The positioning procedure requires 3-4 personnel (two on each side), physician at the head to secure tubes, moving the patient to the bed edge, turning to lateral decubitus, then to prone position, and repositioning to the center of the bed. The section details complications including pressure ulcers, device displacement, facial edema, hemodynamic instability, tube dislodgement, corneal ulcers, and cardiac arrest. Nursing care includes repositioning every two hours, device verification, eye care, pressure ulcer prevention, daily bathing, and special attention to tracheal aspirations.

This section details complications associated with prone positioning: dislodgement of catheters, endotracheal tube, nasogastric tube, and vascular lines; hemodynamic complications including hypotension, bradycardia, tachycardia, and arrhythmias; and pressure ulcers in high-risk areas (face, breasts, genitals, costal regions, knees). The presenter shows clinical evidence of pressure ulcers including nasal fossa lesions, lip lesions, frontal lesions, breast lesions, and tabique nasal lesions. The section emphasizes that 14.6% of intubated patients experience endotracheal tube obstruction.

Prone positioning improves oxygenation in severe ARDS by recruiting collapsed dorsal lung regions, improving ventilation distribution, reducing atelectasis, and improving V/Q matching. Studies demonstrate that positioning patients prone for 16 hours daily can significantly improve PaO2/FiO2 ratios and reduce mortality. Absolute contraindications include: cervical spine injury, recent cardiac surgery requiring sternotomy, and ECMO cannulation at the central venous site. Relative contraindications include: severe obesity, pregnancy (third trimester), uncontrolled hypertension, active bleeding, and uncontrolled seizures. Successful prone positioning requires: adequate staffing (3-5 personnel), specialized equipment (prone positioning bed or mattress), secure endotracheal tube fixation, closed suction system for secretions, and monitoring equipment. Patient preparation includes: securing all lines and tubes with tape, ensuring adequate oxygenation before positioning, administering sedation and analgesia as needed, protecting eyes with lubricating ointment and eye shields, emptying the stomach to prevent aspiration, and documenting tube positions before positioning. The procedure involves positioning on a specialized prone bed, placing pillows under chest, pelvis, and knees, securing tubes, carefully turning the patient prone, and verifying proper positioning. Continuous monitoring includes end-tidal CO2, pulse oximetry, blood pressure, heart rate, and respiratory rate. Success is assessed by improvement in PaO2/FiO2 ratio by at least 20 mmHg after 6 hours. Complications include: endotracheal tube displacement, hemodynamic instability, pressure ulcers, aspiration, and equipment-related complications.

Prone positioning is indicated for ARDS patients with PaO2/FiO2 < 150 showing no improvement. Before proning, assess patient stability, secure access sites, and evaluate for contraindications including hemodynamic instability, arrhythmias, elevated intracranial pressure, and late pregnancy. The wrapping technique uses sheets to create a cocoon for safe repositioning. Endotracheal tube securement requires cuff pressures 20-30 cm H2O to prevent dislodgement and tracheal damage. Closed-system suction minimizes infection risk. Waveform analysis detects secretion accumulation through increased peak pressure and decreased tidal volume.

This segment covers advanced ventilatory strategies and rescue therapies for refractory hypoxemia in ARDS. The open lung strategy combines lung protective ventilation with PEEP optimization and recruitment maneuvers to maintain aeration of functional lung tissue and prevent atelectrauma. Recruitment maneuvers are transient applications of high transpulmonary pressure to reopen collapsed alveoli: Suction recruitment (high TV to specific plateau pressure), Sustained inflation (30-40 cm H2O for 30-40 seconds), and Stepwise recruitment (gradual PEEP increase from 10 to 45 cm H2O over 2 minutes). Stepwise recruitment has advantages with less hemodynamic compromise. Decremental recruitment maneuver titrates optimal PEEP by gradually decreasing FiO2 and peak pressure until saturation drops below 90%. Inverse ratio ventilation (I:E ratio increased from 1:2 to 1.5:1) improves oxygenation by recruiting more alveoli and redistributing edema fluid. Refractory hypoxemia requires rescue measures: HFOV (small tidal volumes 1-2 ml/kg at 300 cycles/min, reduces volutrauma but causes CO2 accumulation), Inhaled nitric oxide (selective pulmonary vasodilator reducing V/Q mismatch), Prone ventilation (PROSEVA trial showed mortality benefit when started within 36 hours), Liquid ventilation (perfluorochemicals with oxygen carrying capacity 3x blood), and ECMO (complete respiratory and circulatory support as final therapy).

APRV (Airway Pressure Release Ventilation) is an advanced mechanical ventilation mode providing continuous positive airway pressure with intermittent brief releases for CO2 removal. It uses four parameters: P_high (20-30 cm H2O, maintains alveolar recruitment), P_low (typically 0 cm H2O), T_high (4-6 seconds at P_high), and T_low (0.5-1 second at P_low). The patient spends most time at P_high for oxygenation, then briefly drops to P_low for exhalation. This allows spontaneous breathing throughout the cycle while maintaining open lung strategy. Indications include ARDS with refractory hypoxemia. Contraindications include severe obstructive lung disease, uncontrolled spontaneous breathing, high intracranial pressure, and hemodynamic instability. Monitoring requires assessing oxygenation, tidal volumes, and auto-PEEP. Adjustments include increasing P_high/T_high for oxygenation and shortening T_high/prolonging T_low for CO2 clearance. Weaning involves gradually lowering P_high and increasing T_high toward CPAP levels.

This extensive section addresses escalation strategies for refractory ARDS management. Key topics include: (1) Advanced mechanical ventilation techniques: recruitment maneuvers (30/30 or 40/40 protocols) for patients with significant atelectasis, though aggressive maneuvers (45 cm H2O for 2 min) have shown harm; body positioning considerations in morbid obesity (initial PEEP 16-20 cm H2O, reverse Trendelenburg or chair position preserves FRC); intubation in upright position (45 degrees) to prevent desaturation; (2) Rescue therapies: prone positioning as the most evidence-based intervention for ARDS patients with PaO2/FiO2 <150 who fail optimized ventilation—posterior basal lung regions receive rich blood supply but poor gas exchange in supine position; neuromuscular blockade (intermittent rather than continuous) for patient-ventilator synchronization; pulmonary vasodilators (nitric oxide or depo-prostacyclin) improve oxygenation but provide no mortality benefit and should not delay life-saving interventions; (3) Extracorporeal support: VV ECMO indications for refractory hypoxemia failing prone positioning, particularly for patients with combined gas exchange and CO2 removal deficits (COPD + pneumonia), unilateral lung disease, or those needing bridging to recovery/transplant.

Corticosteroids improve oxygenation (FACT trial) but mortality benefit remains uncertain. High-frequency ventilation (HFV) was developed to provide ventilation with minimal tidal volumes but showed higher mortality in ARDSnet due to hemodynamic complications. Recruitment maneuvers aim to open collapsed alveoli; short maneuvers (20-40 seconds) are more effective than prolonged ones (15-20 minutes). However, recruitment maneuvers carry risks of hemodynamic compromise and barotrauma. They should be used cautiously in hemodynamically stable patients. Prone ventilation and inverse ratio ventilation are advanced strategies that may improve oxygenation but have not shown consistent mortality benefit.

APRV applies two levels of CPAP with an intermittent release phase for spontaneous breaths. The clinician sets high pressure, low pressure, high time, and low time parameters. This mode is recommended to improve oxygenation and treat refractory hypoxemia, making it suitable for patients with ARDS (acute respiratory distress syndrome), acute lung injury, and sometimes elective cases.

VV-ECMO is indicated when patients cannot be adequately ventilated despite maximal conventional therapy (high PEEP, paralysis, prone positioning, vasodilators). Contraindications include moribund patients, CNS bleeding, and anticoagulation contraindications. Age is variable, with most centers limiting patients to under 70 years. Early intervention (within 7 days) is crucial. Oxygen transport is better understood through content rather than partial pressure—water at 160 mmHg PO2 contains only 0.3 cc oxygen per 100cc, while blood contains 20 cc due to hemoglobin. The hemoglobin dissociation curve is non-linear. The human body tolerates hypoxia remarkably well—mountaineers at Everest summit have PO2 of 24 mmHg yet remain functional. Under normal conditions, the body receives 1 liter oxygen per minute but consumes only 250 ml/min, with 75% saturation in mixed venous blood.

Veno-venous ECMO (VV-ECMO) is a respiratory support system that removes blood from a venous source, passes it through a centrifugal pump and membrane oxygenator, and returns it to the venous system. The system provides oxygenation and CO2 removal without cardiac support. The ECMO console allows adjustment of blood flow rate (determining oxygenation) and gas flow rate (determining CO2 removal). In normal physiology, approximately 100% of cardiac output passes through the lungs for gas exchange. VV-ECMO supplements native lung function by providing additional gas exchange capacity in series with the patient's lungs. As lung function improves, ECMO flow can be proportionally reduced.

Veno-Venous (VV) ECMO provides respiratory support by acting as an artificial lung that removes deoxygenated blood from the venous circulation, oxygenates it through a membrane oxygenator, and returns it to the venous system, thereby allowing the native heart to continue pumping blood to the lungs while providing gas exchange when native lungs are unable to adequately oxygenate blood or remove CO2; it is indicated for severe respiratory failure when safe lung-protective ventilation is not possible, and complications include bleeding, thrombosis, infection, hemolysis, barotrauma, access insufficiency, and recirculation, with weaning achieved by progressively reducing fresh gas flow until it reaches zero for 24 hours.

VV-ECMO (Veno-Venous Extracorporeal Membrane Oxygenation) is a life-sustaining therapy for severe respiratory failure. The ELSO established nomenclature in 2018 distinguishing ECMO (oxygenation) from ECOR (CO2 elimination). VV-ECMO is indicated for: (1) Refractory hypoxemia with PAFI <80 after all treatments including prone positioning; (2) Refractory hypercapnia with pH <7.25 despite minute ventilation optimization; (3) Lung transplant candidates requiring ventilation. Common pathologies include infectious respiratory distress, severe thoracic trauma, pulmonary hemorrhages (now manageable without anticoagulation), and bronchopleural fistulas. Contraindications are primarily relative: severe CNS injury with poor prognosis and prolonged mechanical ventilation with multi-organ dysfunction. The CESAR study (2009) first demonstrated VV-ECMO improves survival and quality of life, while EOLIA (2018) confirmed benefits in multicenter setting. Survival rates are 59% in adults, 62% in pediatrics, and 72% in neonates, representing patients with baseline mortality exceeding 80%. VV-ECMO is a supportive strategy, not a treatment, designed to improve oxygenation and oxygen transport while allowing native lung recovery. The primary mortality reduction mechanism is indirect: ultra-protective ventilation reduces ventilator-induced lung injury (VILI) and cytokine release causing multi-organ dysfunction. Ventilation parameters include tidal volumes of 2-3 ml/kg, PIP of 10-12 cm H2O, and respiratory rates of 8-10 breaths/min. Standard cannulation uses femoral venous drainage (tip in retrohepatic IVC) and jugular venous return. Alternative strategies include VPA-ECMO for right ventricular dysfunction. Recirculation occurs when cannulas are too close. Oxygenation targets are PaO2 50-60 mmHg and saturation 88-92%, with hemoglobin maintained at 10-14 g/dL. Flow rates target 50-70 ml/kg/min in adults, 80-120 ml/kg/min in pediatrics, and 100-150 ml/kg/min in neonates, aiming for 60% of cardiac output. CO2 is managed via fresh gas flow (4-5 L/min starting point in adults), adjusted gradually to avoid neurological complications. VV-ECMO is a series circuit with distinct oxygenation dynamics: venous return has low oxygen content; drainage cannula slightly increases content; membrane oxygenator significantly increases content (PaO2 >200 mmHg); right ventricle mixes oxygenated blood with native venous return, reducing content; lungs (if functional) contribute to oxygenation; systemic circulation receives mixed blood. When desaturation occurs, first check blender oxygen supply. If adequate, obtain pre-membrane and post-membrane samples. High pre-membrane with low post-membrane indicates membrane dysfunction (decreased transfer capacity). Low pre-membrane indicates recirculation or increased oxygen consumption. Membrane dysfunction manifests as coagulopathy, decreased oxygen/CO2 transfer, and increased transmembrane pressures. CO2 difference <10 mmHg indicates membrane dysfunction. Delta pressure monitoring is essential, with increasing delta pressure suggesting membrane obstruction requiring replacement.

VV-ECMO (Veno-Venous Extracorporeal Membrane Oxygenation) substitutes pulmonary function by facilitating gas exchange (O2 addition and CO2 removal). It requires only venous access (jugular or femoral) with dual-lumen cannulas. Blood flow ranges 100-120 cc/kg/min. The device can increase cardiac output by 30-90% but provides no direct cardiac support. Average duration is 21 days. Oxygenation and CO2 removal efficiency range 20-90% depending on membrane technology. Indications include severe ARDS (P/F ratio <100 on 100% FiO2, shunt >30%), pneumonia, pulmonary contusion, and status asthmaticus refractory to treatment. Contraindications include age >70, advanced lung disease, anticoagulation contraindication, and prolonged ventilation (>5 days). Timing is critical: early initiation within 24 hours yields 60% survival, while initiation after 72 hours drops to 40%.